In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TG Therapeutics Inc.

www.tgtherapeutics.com

Latest From TG Therapeutics Inc.

Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases

Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.

Financing Business Strategies

Keeping Track: Bad News For Bristol And Lilly, Good News For TG Therapeutics

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

Verastem’s Copiktra Gets Early Approval To Challenge Zydelig, Venclexta In Third-Line CLL

Copiktra (duvelisib) becomes the first dual inhibitor of PI3K delta and gamma to hit the market, placing it in competition with Gilead’s Zydelig and AbbVie’s Venclexta.

Approvals Cancer

Deal Watch: Amazon Moves Into Rx Services With Acquisition Of PillPack

Celgene makes play into RNA-expression correction via neuroscience partnership and equity investment with Skyhawk. Novartis’ Sandoz agreed to commercialize Adamis’ Symjepi, a competitor to EpiPen, in the US.

Deals Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Atlantic Technology Ventures Inc.
  • Manhattan Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • TG Therapeutics Inc.
  • Senior Management
  • Michael S Weiss, Pres. & CEO
    Sean A Power, CFO
    Adam Waldman, Chief Commercial Officer
  • Contact Info
  • TG Therapeutics Inc.
    Phone: (212) 554-4484
    2 Gansevoort St.
    9th Floor
    New York , NY 10014
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register